Moderna, Merck breakthrough could usher in wave of cancer vaccines

Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor

The treatment involves pairing Merck's immunotherapy drug with a customized mRNA vaccine that instructs the immune system to attack specific cancer cells.

Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna's shares surging as much as 160%.

New Melanoma Vaccine Shows Promise In Fighting Cancer, Preventing Recurrence  HuffPost

Moderna, Merck breakthrough could usher in wave of cancer vaccines  Reuters

Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The vaccine reportedly thwarted the cancer's return and spread.

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

A cancer vaccine developed by Merck and Moderna treating patients with melanoma showed positive and promising late-stage testing results.

Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Moderna-Merck melanoma therapy averts cancer recurrence in study  Chicago Tribune

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner

Moderna shares surge as melanoma vaccine with Merck succeeds in large trial  CNN

The mRNA-based vaccine combined with Keytruda reduced melanoma recurrence in more than 1,100 patients whose cancer had been surgically removed